KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Assets (2016 - 2025)

Historic Current Assets for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $480.1 million.

  • Xenon Pharmaceuticals' Current Assets fell 2721.22% to $480.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $480.1 million, marking a year-over-year decrease of 2721.22%. This contributed to the annual value of $635.3 million for FY2024, which is 150.37% down from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Current Assets is $480.1 million, which was down 2721.22% from $500.3 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Current Assets high stood at $794.8 million for Q2 2022, and its period low was $256.3 million during Q3 2021.
  • Moreover, its 5-year median value for Current Assets was $559.0 million (2021), whereas its average is $551.9 million.
  • Its Current Assets has fluctuated over the past 5 years, first soared by 20752.05% in 2021, then crashed by 3147.79% in 2023.
  • Xenon Pharmaceuticals' Current Assets (Quarter) stood at $559.0 million in 2021, then rose by 7.38% to $600.3 million in 2022, then grew by 7.44% to $645.0 million in 2023, then fell by 1.5% to $635.3 million in 2024, then dropped by 24.42% to $480.1 million in 2025.
  • Its last three reported values are $480.1 million in Q3 2025, $500.3 million for Q2 2025, and $565.5 million during Q1 2025.